WO2007057762A3 - Osmotic bi-layer tablet - Google Patents

Osmotic bi-layer tablet Download PDF

Info

Publication number
WO2007057762A3
WO2007057762A3 PCT/IB2006/003255 IB2006003255W WO2007057762A3 WO 2007057762 A3 WO2007057762 A3 WO 2007057762A3 IB 2006003255 W IB2006003255 W IB 2006003255W WO 2007057762 A3 WO2007057762 A3 WO 2007057762A3
Authority
WO
WIPO (PCT)
Prior art keywords
layer
drug
water
osmotic
average molecular
Prior art date
Application number
PCT/IB2006/003255
Other languages
French (fr)
Other versions
WO2007057762A2 (en
Inventor
Leah Elizabeth Appel
Corey Aaron Brown
Janet Sarah Burton
Hiep Huatan
Nicoletta Loggia
Danielle Supplee
Original Assignee
Pfizer Ltd
Leah Elizabeth Appel
Corey Aaron Brown
Janet Sarah Burton
Hiep Huatan
Nicoletta Loggia
Danielle Supplee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd, Leah Elizabeth Appel, Corey Aaron Brown, Janet Sarah Burton, Hiep Huatan, Nicoletta Loggia, Danielle Supplee filed Critical Pfizer Ltd
Publication of WO2007057762A2 publication Critical patent/WO2007057762A2/en
Publication of WO2007057762A3 publication Critical patent/WO2007057762A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)

Abstract

An osmotic bi-layer tablet for the controlled release of a low-solubility drug comprises an inner core containing a drug-containing layer and a water-swellable layer, and a water-permeable outer coating including at least one delivery port, wherein the drug- containing layer comprises a drug substance, polyethylene oxide polymer having an average molecular weight from about 200,000 to 600,000Da, and an osmogen, and the water-swellable layer comprises polyethylene oxide polymer having a weight average molecular weight of from about 4,000,000 to about 7,000,000Da and a sweller layer strengthening agent.
PCT/IB2006/003255 2005-11-16 2006-11-10 Osmotic bi-layer tablet WO2007057762A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73770305P 2005-11-16 2005-11-16
US60/737,703 2005-11-16

Publications (2)

Publication Number Publication Date
WO2007057762A2 WO2007057762A2 (en) 2007-05-24
WO2007057762A3 true WO2007057762A3 (en) 2008-04-10

Family

ID=38049018

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/003255 WO2007057762A2 (en) 2005-11-16 2006-11-10 Osmotic bi-layer tablet

Country Status (1)

Country Link
WO (1) WO2007057762A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637080B2 (en) 2007-06-28 2014-01-28 Osmotica Kereskedelmi és Szolgáltató, KFT Rupturing controlled release device comprising a subcoat
JP2011512349A (en) * 2008-02-15 2011-04-21 サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッド Oral controlled release tablets
DE102009016584A1 (en) * 2009-04-06 2010-10-07 Ratiopharm Gmbh Orodispersible tablet containing a sildenafil salt
WO2011039686A1 (en) * 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine oral sustained release dosage forms
JP6041823B2 (en) * 2013-03-16 2016-12-14 ファイザー・インク Tofacitinib oral sustained release dosage form

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010044474A1 (en) * 1999-12-23 2001-11-22 Curatolo William J. Hydrogel-driven layered drug dosage form
US20020015731A1 (en) * 1999-12-23 2002-02-07 Appel Leah E. Hydrogel-Driven Drug Dosage Form
US20030215510A1 (en) * 1991-06-27 2003-11-20 Frank Jao System for delaying drug delivery up to seven hours
WO2005016306A2 (en) * 2003-08-06 2005-02-24 Alza Corporation Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
WO2007003330A2 (en) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmaceutical dosage form containing an active principle combination of nifedipine and/or nisoldipine and of an angiotensin ii antagonist

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215510A1 (en) * 1991-06-27 2003-11-20 Frank Jao System for delaying drug delivery up to seven hours
US20010044474A1 (en) * 1999-12-23 2001-11-22 Curatolo William J. Hydrogel-driven layered drug dosage form
US20020015731A1 (en) * 1999-12-23 2002-02-07 Appel Leah E. Hydrogel-Driven Drug Dosage Form
WO2005016306A2 (en) * 2003-08-06 2005-02-24 Alza Corporation Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
WO2007003330A2 (en) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmaceutical dosage form containing an active principle combination of nifedipine and/or nisoldipine and of an angiotensin ii antagonist

Also Published As

Publication number Publication date
WO2007057762A2 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
WO2006101815A3 (en) Pharmaceutical compositions comprising polyoxaester and active agents for use with osmotic delivery systems
WO2007133583A3 (en) Zero-order modified release solid dosage forms
WO2007070649A3 (en) Antimicrobial coating system
WO2006030402A3 (en) Dual compartment osmotic delivery device
WO2006017245A3 (en) Sulfonated styrene polymers for medical articles
DE60005819D1 (en) TASTE-MASKED ORAL PHARMACEUTICAL COMPOSITIONS WITH CONTROLLED DELIVERY
CA2395333A1 (en) Hydrogel-driven drug dosage form
WO2005097064A3 (en) Taste-masked drugs in rupturing multiparticulates
WO2008100375A3 (en) Polymer-based films and drug delivery systems made therefrom
MXPA03012041A (en) Gastric retention controlled drug delivery system.
SI1828330T1 (en) Polysilazane-based coating and use thereof for coating films, especially polymer films
HK1090936A1 (en) Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
MY148867A (en) Gastric retention drug delivery system
WO2008148798A3 (en) Controlled release pharmaceutical compositions for prolonged effect
EP1832289A3 (en) Compositions and coatings for implantable medical devices
WO2005027794A3 (en) Medical devices
WO2007057762A3 (en) Osmotic bi-layer tablet
DE69917866D1 (en) Tablets containing bupropion hydrochloride with controlled drug delivery
WO2009055306A3 (en) Coating designs for the tailored release of dual drugs from polymeric coatings
WO2008094834A3 (en) Multi-functional drug carriers
WO2009154810A3 (en) Delivery systems for multiple active agents
WO2006024944A3 (en) Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
WO2007122510A3 (en) Asymmetric membranes for drug delivery devices
WO2009001099A3 (en) A pharmaceutical composition comprising polyaphron dispersion
WO2008070356A3 (en) Block biodegradable copolymers for medical devices

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06809236

Country of ref document: EP

Kind code of ref document: A2